Vascepa Negative Panel Vote Clouds Future For Other Cholesterol Drugs
A broader indication needs cardiovascular outcomes data, FDA’s advisory committee says, and the agency seems to agree that new cholesterol-lowering drugs need stronger endpoints.
A broader indication needs cardiovascular outcomes data, FDA’s advisory committee says, and the agency seems to agree that new cholesterol-lowering drugs need stronger endpoints.